Literature DB >> 26768688

Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.

Eva Rettinger1, Sabine Huenecke2, Halvard Bonig3, Michael Merker2, Andrea Jarisch2, Jan Soerensen2, Andre Willasch2, Gesine Bug4, Ansgar Schulz5, Thomas Klingebiel2, Peter Bader1.   

Abstract

Entities:  

Keywords:  HSCT; IL-15-activated; cytokine-induced killer cells; efficacy; immunological control; relapse

Mesh：

Substances：

Year:  2016        PMID： 26768688      PMCID： PMC5004389          DOI： 10.3324/haematol.2015.138016

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.

Authors:  A C Lankester; M B Bierings; E R van Wering; A J M Wijkhuijs; R A de Weger; J T Wijnen; J M Vossen; B Versluys; R M Egeler; M J D van Tol; H Putter; T Révész; J J M van Dongen; V H J van der Velden; M W Schilham
Journal:  Leukemia       Date:  2010-06-10       Impact factor: 11.528

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 4.  Haploidentical transplantation for leukemia.

Authors:  Junya Kanda; Nelson J Chao; David A Rizzieri
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

5.  Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.

Authors:  Hilary L Haines; Jack J Bleesing; Stella M Davies; Lindsey Hornung; Michael B Jordan; Rebecca A Marsh; Alexandra H Filipovich
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-18       Impact factor: 5.742

6.  HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Authors:  Amer M Zeidan; Patrick M Forde; Heather Symons; Allen Chen; B Douglas Smith; Keith Pratz; Hetty Carraway; Douglas E Gladstone; Ephraim J Fuchs; Leo Luznik; Richard J Jones; Javier Bolaños-Meade
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

7.  Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?

Authors:  Peter Bader; Hermann Kreyenberg; Walter Hoelle; Gregor Dueckers; Rupert Handgretinger; Peter Lang; Bernhard Kremens; Dagmar Dilloo; Karl-Walter Sykora; Martin Schrappe; Charlotte Niemeyer; Arend Von Stackelberg; Bernd Gruhn; Günter Henze; Johann Greil; Dietrich Niethammer; Klaus Dietz; James F Beck; Thomas Klingebiel
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

8.  Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?

Authors:  Adriana Balduzzi; Lucia Di Maio; Daniela Silvestri; Simona Songia; Sonia Bonanomi; Attilio Rovelli; Valentino Conter; Andrea Biondi; Giovanni Cazzaniga; Maria G Valsecchi
Journal:  Br J Haematol       Date:  2014-02       Impact factor: 6.998

9.  Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.

Authors:  Martino Introna; Gianmaria Borleri; Elena Conti; Marta Franceschetti; Anna Maria Barbui; Raewyn Broady; Erica Dander; Giuseppe Gaipa; Giovanna D'Amico; Ettore Biagi; Matteo Parma; Enrico M Pogliani; Orietta Spinelli; Donatella Baronciani; Anna Grassi; Josée Golay; Tiziano Barbui; Andrea Biondi; Alessandro Rambaldi
Journal:  Haematologica       Date:  2007-07       Impact factor: 9.941

10.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

Authors:  I G Schmidt-Wolf; R S Negrin; H P Kiem; K G Blume; I L Weissman
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307
View more
  13 in total

Review 1.  Cells to prevent/treat relapse following allogeneic stem cell transplantation.

Authors:  Andrew C Dietz; Alan S Wayne
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.

Authors:  A M Willasch; E Salzmann-Manrique; T Krenn; M Duerken; J Faber; J Opper; H Kreyenberg; R Bager; S Huenecke; C Cappel; M Bremm; V Pfirrmann; M Merker; E Ullrich; S Bakhtiar; E Rettinger; A Jarisch; J Soerensen; T E Klingebiel; P Bader
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

3.  Association of IL-15 and IP-10 Serum Levels with Cytomegalovirus Infection, CMV Viral Load and Cyclosporine Level after Kidney Transplantation.

Authors:  Reza Asadzadeh; Pedram Ahmadpoor; Mohsen Nafar; Shima Samavat; Hassan Nikoueinejad; Morteza Hosseinzadeh; Nahid Mamizadeh; Saeideh Hatami; Elham Masoumi; Aliakbar Amirzargar
Journal:  Rep Biochem Mol Biol       Date:  2021-07

Review 4.  Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.

Authors:  Roberto Limongello; Andrea Marra; Antonella Mancusi; Samanta Bonato; Eni Hoxha; Loredana Ruggeri; Susanta Hui; Andrea Velardi; Antonio Pierini
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

5.  Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.

Authors:  Melanie Bremm; Lisa-Marie Pfeffermann; Claudia Cappel; Verena Katzki; Stephanie Erben; Sibille Betz; Andrea Quaiser; Michael Merker; Halvard Bonig; Michael Schmidt; Thomas Klingebiel; Peter Bader; Sabine Huenecke; Eva Rettinger
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

6.  Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy.

Authors:  Yun Zhou; Chang-Long Chen; Sen-Wei Jiang; Yanling Feng; Linjing Yuan; Ping Chen; Lan Zhang; Shuting Huang; Jundong Li; Jian-Chuan Xia; Min Zheng
Journal:  Oncoimmunology       Date:  2018-11-11       Impact factor: 8.110

7.  In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.

Authors:  Melanie Bremm; Sabine Huenecke; Olga Zimmermann; Verena Pfirrmann; Andrea Quaiser; Halvard Bonig; Jan Soerensen; Thomas Klingebiel; Eva Rettinger; Peter Bader; Claudia Cappel
Journal:  J Transl Med       Date:  2016-09-13       Impact factor: 5.531

Review 8.  Innovative Clinical Perspectives for CIK Cells in Cancer Patients.

Authors:  Martino Introna; Fabio Correnti
Journal:  Int J Mol Sci       Date:  2018-01-25       Impact factor: 5.923

9.  Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.

Authors:  Michael Merker; Verena Pfirrmann; Sarah Oelsner; Simone Fulda; Thomas Klingebiel; Winfried S Wels; Peter Bader; Eva Rettinger
Journal:  Oncotarget       Date:  2017-08-02

Review 10.  Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.

Authors:  Peter Valent; Karin Bauer; Irina Sadovnik; Dubravka Smiljkovic; Daniel Ivanov; Harald Herrmann; Yüksel Filik; Gregor Eisenwort; Wolfgang R Sperr; Werner Rabitsch
Journal:  Stem Cells Transl Med       Date:  2020-07-13       Impact factor: 6.940
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.